Conference Handbook 2017
Translating UK scientific excellence into global therapeutic strategies
Partnering for scientific leadership At AstraZeneca, we believe in the power of what science can do to transform serious diseases like cancer, heart disease, diabetes, COPD and asthma. We also know that breakthrough science doesn’t happen in isolation. It happens through partnership.
Our expertise spans the entire life-cycle of a medicine and we have a rare combination of discovery and development strengths in small molecules and biologics, immunotherapies, protein engineering technologies and devices. These are reinforced by a strong focus on translational science and personalised healthcare.
To find out more, visit astrazeneca.com/Partnering
What science can do Circulating tumour DNA AstraZeneca has pioneered the use of circulating tumour DNA (ctDNA) in the diagnosis of cancer. Pieces of DNA break off from a tumour and circulate in the bloodstream where they can be analysed to give genetic information about a patient’s tumour. This allows healthcare professionals to determine the right treatment for the patient using a non-invasive blood test.
Atlas approval ID: 999,822.011 Expires August 2017
33 ON Helix 2017 Sponsors Platinum Sponsors
contents Welcome
Silver Sponsors
4
Keynote Speakers Speaker Profiles
7-8 10-11 & 14
Programme
12
Floor Plan
13
Workshop
15
Exhibitor Profiles
Bronze Sponsors
Media Partners
Dates for your Diary 2017
Corporate Patron
Event Supporters
Corporate Sponsors
Partnering powered by Keep up with the conversation #ONHelix17
17-21 22
4 welcome
welcome Dear ON Helix Participant, Harriet Fear CEO, One Nucleus
Welcome to our Translational Research Conference: ON Helix. One of the key issues described by many researchers is how to overcome the innovation gaps on the translational research pathway. This includes identifying barriers on which to concentrate, finding funding and meeting the right networks. These topics are of course covered by many conferences, but with ON Helix, One Nucleus brings together all these elements in one event under one roof for one day. Excellence in translational research is a core skill of many One Nucleus members and it seemed entirely appropriate that we should showcase that excellence to the UK and wider community; especially if it will stimulate and inspire young and emerging companies to follow in the footsteps of the people you will hear and learn from today. ON Helix aims to inform delegates how to turn early stage inventions and ideas into innovative health treatments. We will present the UK landscape of the business environment, funding, scientific and clinical research excellence. It will be a unique knowledge-sharing environment between academia and business. We are over the moon that we have some of the worlds’ best in our Keynote Speaker line-up – never before seen together on the same day!
ON Helix was launched in July 2013 to great acclaim with Sir William Castell, the then Chair of the Wellcome Trust who opened it, describing it as ‘a great day with a fantastic line-up (and) a great showcase for the strength of biomedical innovation’. Sir Mike Rawlins followed up by declaring it ‘THE translational event in the UK – it’s terrific’. So we decided to make it an annual fixture. You can expect stimulating keynote speeches, exceptional world class case study examples of collaborations and technologies and plenty of networking. The One Nucleus team and I know you will make full use of the presentations, debate, networking and the exhibitions to catch up with old friends and make some new ones, update yourselves on trends in the sector and create and scope out new business opportunities. I would like to take this opportunity to thank our fantastic ON Helix Advisory Board for all their support, all our sponsors and speakers for making it possible and of course you, our delegates, for bringing the event to life. I wish everyone an excellent event.
5
Innovative Drug Discovery Focused Drug Development Astex is a leader in innovative drug discovery and development, committed to the fight against cancer and diseases of the central nervous system. As part of Japan’s leading pharmaceutical company, Otsuka Pharmaceutical Co. Ltd., Astex operates from two sites with drug discovery research headquarters in Cambridge, UK and clinical development headquarters in Pleasanton, California, USA. www.astx.com
keynote speakerss7
Sara-Jane Dunn
Scientist, Microsoft Research Sara-Jane Dunn is a Scientist at Microsoft Research, Cambridge. She studied Mathematics at the University of Oxford, graduating with a MMath in 2007. She remained in Oxford for her doctoral research, as part of the Computational Biology group at the Department of Computer Science. In 2012, she joined Microsoft Research as a Postdoctoral Researcher, before transitioning to a permanent scientist role in 2014. In 2016, she was invited to become an Affiliate Researcher of the Wellcome Trust-Medical Research Council Stem Cell Institute, University of Cambridge. Her research focuses on uncovering the fundamental principles of biological information-processing, particularly investigating decision-making in development.
Peter Jackson
Executive Director, The AMR Centre Dr Peter Jackson is Executive Director of the AMR Centre – a UK public-private partnership focused on antimicrobial resistance R&D, and an alliance member of the transatlantic CARB-X initiative. An experienced life sciences entrepreneur, Dr Jackson is the founder of six life sciences ventures over the past 10 years. Before that, he had over 15 years in the sector, previously holding senior executive roles as a Commercial Director and then Head of Avecia’s Pharmaceutical Products business unit, following senior commercial and R&D positions at Zeneca and ICI. Dr Jackson was also a Founder Director of the National Skills Academy for Process Industries.
David Pardoe
Head of Innovation and Initiatives, LifeArc Dr David Pardoe is Head of Innovation and Initiatives at LifeArc. He works with research charities, academia and industrial partners to accelerate and promote new medicines to patients. He has an extensive 25 year background in developing new research tools in medicinal chemistry, where he has been instrumental in delivering four candidate medicines to the clinic including frovatriptan for the control of migraine. After leaving a management position at GlaxoSmithKline, David spent seven years working across the healthcare value chain in bringing new diagnostics, devices and drugs to patients before joining LifeArc (formerly MRC Technology) in 2013.
8 keynote speakers
Sir Michael Rawlins
Chairman, Medicines and Healthcare Products Regulatory Agency (MHRA) Sir Michael is Chairman of the Medicines and Healthcare Products Regulatory Agency (since December 2014). He is a Clinical Pharmacologist and Specialist in internal medicine. He was Professor of Clinical Pharmacology in Newcastle, and Physician at the Newcastle Hospitals, from 1999-2006. He was Chairman of the Committee on Safety of Medicines (1992-1998), Chairman of the Advisory Council on the Misuse of Drugs (1998-2008) and Founding Chairman of the National Institute for Clinical Excellence (1999-2013). He is recent past President of the Royal Society of Medicine (2012-2014). Currently Sir Michael is Chairman of UK Biobank, Honorary Professor at the London School of Hygiene and Tropical Medicine, and Emeritus Professor at the University of Newcastle upon Tyne. Sir Michael was appointed the Chairman of the Medicines and Healthcare Products Regulatory Agency (MHRA), on 1st December 2014.
Sharon Vosmek CEO, Astia
Sharon Vosmek has transformed Astia during her tenure as CEO since 2007, having
previously served as COO from 2004. Under Ms. Vosmek’s leadership, Astia is now the preeminent organisation working to ensure the success of high-growth startups founded and led by women. Ms. Vosmek has led Astia’s growth from 20 individuals in Silicon Valley to the global community of more than 5,000 investors, entrepreneurs, family offices, industry leaders and individuals that it is today. Ms Vosmek was one of the founding managers and members of Astia Angels, the global investment group launched in 2013 to invest directly into womenled high-growth companies. Ms. Vosmek is well-regarded around the globe for her opinions, research and commentary on the importance of women leaders as integral to innovation and high-performing entrepreneurial companies. A highly sought-after speaker, Ms. Vosmek has most recently spoken at the United Nations, the Milken Institute CA Summit, given lectures at numerous Universities most notably on the topic of building inclusive ecosystems at Stanford and MIT, was invited to participate in The White House Women’s Entrepreneurship Conference; the Presidential Summit on Entrepreneurship led by Secretary of State Hillary Clinton; and in 2011 she was a US Delegate to the Asia-Pacific Economic Cooperation (APEC) Women and the Economy Summit. She is also on the Advisory Boards of two venture capital firms, StarVest Partners and Illuminate Ventures; the Stevenage Bioscience Catalyst Experts Advisory Group; the AAAS-Lemelson Invention Ambassadors Advisory Committee; and on the “Making Value for America” expert advisory committee for the National Academy of Engineering.
Where Life Meets Science
Chesterford Research Park offers state of the art laboratory and office space alongside superb central facilities a community perfectly positioned for today’s thriving pharmaceutical and biotech companies. WWW.CHESTERFORDRESEARCHPARK.COM
01223 358114 dodson-jones.co.uk
DODSON JONES C H A R TE R E D S UR V E Y O R S
savills.co.uk
01223 347 000
10 speaker profiles Trevor Baglin Venture Partner, Medicxi Trevor Baglin is a Venture Partner at Medicxi, a life sciences-focused investment firm. He was a Founder-Director of Xo1 Ltd, which was acquired by Janssen Pharmaceuticals in 2015. He is also a Founder of Apcintex Ltd and Super X Ltd. He was Consultant Haematologist to Cambridge University Hospitals for 27 years during which time he served as President of the British Society for Haematology and President of the British Society for Haemostasis and Thrombosis. His main research interests were in personalised risk profiling and the molecular basis of regulation of blood coagulation.
Billy Boyle
Co-Founder and CEO, Owlstone Medical Billy Boyle is an engineering graduate from Cambridge University. He co-founded Owlstone Inc, spun out of Cambridge in 2004. He initially worked on the core microchip technology and is co-inventor on 19 patents. Billy focussed on medical diagnostic applications of FAIMS technology after his wife was diagnosed and later died of colon cancer as a result of a late diagnosis. Billy worked with clinical partners to integrate FAIMS into the world’s largest breath-based clinical trials. Owlstone Medical Ltd spun out in 2016, and has attracted $23.5m investment. Owlstone Medical’s mission is to save 100,000 lives and $1.5B in healthcare costs.
Jane Dancer CBO, F-star Jane joined F-star as their Chief Operating Officer in April 2012. Prior to that she was VP Business Development at Cellzome and Director, Business Development at MedImmune Ltd (formerly Cambridge Antibody Technology (CAT)). Jane spent the first part of her career in the agrochemical industry where she held research and project management roles in Aventis Crop Science, AgrEvo UK Ltd and Schering Agrochemicals Ltd. Jane has an MBA from The Judge Institute of Management Studies, University of Cambridge and a PhD and degree in Natural Sciences from the University of Cambridge.
Hakan Goker
Senior Investment Director, Merck Ventures Hakan Goker (PhD) is a Senior Investment Director at Merck Ventures, corporate venture arm of the biopharmaceutical division of Merck KGaA, Darmstadt, Germany. Hakan joined Merck Ventures in 2013 and previously was investing as a Partner at Aescap Venture and prior to that at Atlas Venture. Since 2006, Hakan was instrumental in the creation, financing, and strategy of multiple biotechnology companies globally including Asceneuron (CH), Orphazyme (DK), Nimbus Discovery (US), F Star (NL), Bicycle Therapeutics (UK) and Nitec now Horizon Pharma (CH/US). Hakan received his PhD in cancer biology from the Institute of Cancer Research/ University of London and continued his scientific career with post-doctoral work at the Breakthrough Breast Cancer Centre/ Royal Marsden Hospital. He gained his BSc Honours from University College London. Hakan is a Board Member of Asceneuron, Artios Pharma, Forendo, Raze Therapeutics, Tocopherx, Synaffix, and Storm Therapeutics.
Lars Gredsted
Partner, Wellcome Trust Lars is a Partner in the Innovations division at the Wellcome Trust which he joined in 2010. He is involved in all stages of the sourcing of new charitable investment opportunities, contract negotiations and management and oversight of funded projects/companies (including board and or steering group representation). He previously worked with in-licensing of early stage research projects at Union Life Sciences in Oxford. Lars has also worked as a Management Consultant with the Boston Consulting Group, where he developed marketing strategies for companies in the life science and industrial biotech areas. Lars gained his PhD from the European Molecular Biology Laboratory (EMBL)/ Heidelberg University and subsequently worked as a postdoc at EMBL in Heidelberg and at the Biotech Research and Innovation Center (BRIC) in Copenhagen. In addition to his PhD, Lars holds an MPhil in Bioscience Enterprise from Cambridge University and a Master of Biochemistry from the University of Copenhagen.
Jackie Hunter CEO, BenevolentAI Jackie Hunter is currently the Chief Executive Officer of Benevolent Bio, a company which uses AI to augment the research capabilities of its drug scientists in order to gain new insights for drug discovery and development. Jackie has over thirty years of experience in the bioscience research sector, working across academia and industry including leading neurology and gastrointestinal drug discovery and early clinical development for GlaxoSmithKline. In that role she oversaw the entry of over 20 compounds into clinical studies and the conduct of 17 Proofs of Concept. Professor Hunter has served on numerous academic, industry and government Boards and panels in both Europe and America. For example, she was involved in the establishment of the Innovative Medicines Initiative (IMI), a 2B euro public-private partnership between the pharmaceutical industry and the European Commission. She served on the IMI Board and was Chair of the EFPIA Research Directors Group. She founded OI Pharma Partners in 2010 and most recently became CEO of the Biotechnology and Biological Sciences Research Council. She holds a personal chair from St George’s Hospital Medical School, which was awarded in recognition of her contribution to bioscience research. In 2010 she was awarded a CBE in the Queen’s Birthday Honours list for Services to the Pharmaceutical Industry.
speaker profiles 11 Harren Jhoti
President and CEO, Astex Pharmaceuticals Harren Jhoti co-founded Astex in 1999 and was Chief Scientific Officer until November 2007 when he was appointed Chief Executive. He also served as President and Member of the Board of Directors of Astex Pharmaceuticals Inc., following the merger of Astex with SuperGen Inc., (subsequently renamed Astex Pharmaceuticals Inc.) in July 2011. Dr. Jhoti was elected a Fellow of the Royal Society of Chemistry in 2016 and of the Academy of Medical Sciences in 2015. He was awarded the Prous Institute-Overton and Meyer Award for New Technologies in Drug Discovery by the European Federation for Medicinal Chemistry in 2012 and was also named by the Royal Society of Chemistry as “Chemistry World Entrepreneur of the Year” for 2007. He has published widely including in leading journals such as Nature and Science and has also been featured in TIME magazine after being named by the World Economic Forum a Technology Pioneer in 2005. Dr. Jhoti previously served on the board of the BIA, the UK BioIndustry Association and currently consults for Life Science Venture Capital firms. Before founding Astex in 1999, he was Head of Structural Biology and Bioinformatics at GlaxoWellcome in the United Kingdom (1991-1999). Prior to Glaxo, Dr. Jhoti was a Post-Doctoral Scientist at Oxford University.
Tony Kouzarides
Director, The Milner Therapeutics Institute Tony Kouzarides (PhD, FMedSci, FRS) is a Cancer Research UK Gibbs Fellow and a Professor of Cancer Biology at the University of Cambridge. He is Deputy Director of the Gurdon Institute, where he has a research laboratory investigating epigenetic pathways and their role in cancer. He is Director of the Milner Therapeutics Institute, designed to exploit industry-academia interactions towards the development of drug therapies. Tony did his degree at the University of Leeds, a PhD at the University of Cambridge and postdoctoral research at the Laboratory of Molecular Biology and New York University Medical Centre, before becoming a group leader at the Gurdon Institute. Tony is a Co-Founder and Director (1998 - 2012) of Abcam plc, a publicly trading antibody reagents company, CoFounder and Director (2001- 2003) of Chroma therapeutics and Co-Founder and Director (2016 - present) of STORM Therapeutics, two UK based cancer drug discovery companies. He is the Founder and Director (2008 - 2012) of a charity “Vencer el Cancer” (Conquer Cancer), based in Spain, which raises public funds for cancer research. He is a Founder and Director (2017) of Cambridge Gravity, a fundraising vehicle for science at the University of Cambridge.
Allan Marchington
Senior Advisor, Apposite Capital and Venture Partner, Touchstone Innovations Allan Marchington is an experienced investor with a strong track record of success. In 2006 Allan and his Partners founded Apposite Capital, an international healthcare investment company based in London. While at Apposite Allan has served on the Board of a number of companies including Calchan Ltd., Birdrock Bio Inc., Ambrx Inc., Ambit Biosciences Inc., Convergence Pharmaceuticals Ltd, and Sotera Wireless. Prior to establishing Apposite, Allan worked in a number of senior roles, including Entrepreneur in Residence, Abingworth Management and Senior Vice President, Millennium Pharmaceuticals Inc. based in Cambridge Mass. Prior to Millennium, Allan was Principal Founder and CEO of Cambridge Combinatorial, a combinatorial chemistry company which was successfully sold to Millennium in 2000. Allan has a PhD in Chemistry from the University of Liverpool and after leaving University, worked for seven years in a range of therapeutic areas at Pfizer.
Eric Mayes
CEO, Endomag Dr Eric Mayes is CEO of Endomag and has over 15 years’ experience in developing and leading materials technology companies spanning data storage, display technology, printed electronics and medical devices. Eric has led the oncology-focused Endomag through rapid growth since marketing its first nanoparticle device for staging breast cancer in late 2012. Prior to joining Endomag in 2010, Eric served as Director of Commercial Development for Cambridge Display Technology (CDT) that was sold to Sumitomo Chemical in 2007 for $285m. Prior to CDT, he served as CEO of NanoMagnetics that developed high performance materials for the data storage industry. For that founding role, he was named the Royal Society of Chemistry’s “Entrepreneur of the Year 2003”. With a strong interest in supporting the translation of scientific research, Eric lectures internationally on nanomaterials commercialisation and technology entrepreneurship. He is an Advisor to the University of Texas at Austin’s “Texas Health Catalyst” and the European Nanomedicine Translation Advisory Board (TAB). A US-UK dual national, he holds a BSc in Physics from Arkansas State University and a PhD in Chemistry from the University of Bath. Eric is a Fellow of the Royal Society of Chemistry.
12 programme 08.00
Registration
08.50
Welcome from One Nucleus
09.20
Keynote Addresses
09.20
Putting the C in Science: Commercialisation, Community and Capital
Sharon Vosmek Astia
09.50
Time for a Change‌
David Pardoe LifeArc
10.20
Accelerating the Antibiotics Pipeline: AMR Centre and CARB-X
Peter Jackson The AMR Centre
10.50
Coffee Break
11.20
Session 1: Choosing the Right Business Model Chair
Panellists
Harren Jhoti Astex Pharmaceuticals
Jane Dancer F-star
Harriet Fear One Nucleus
RenĂŠ van der Merwe MedImmune
12.20
Lunch, Exhibition and Ice Cream Van
13.00
Workshop by UCL Translational Office (See Floor Plan for Location)
14.00
Keynote Address From Understanding Biological Computation to Programming Cells
14.30
Tony Kouzarides The Milner Therapeutics Institute
Trevor Baglin Medicxi
Sara-Jane Dunn Microsoft Research
Session 2: New Technologies in Translational Medicine Chair
Panellists
Claire Thompson Agility Health Tech
Jackie Hunter BenevolentAI
Eric Mayes Endomag
15.30
Coffee Break
16.15
Session 3: Do Charities Make the Best Investors?
Sponsored by
Chair
Panellists
Magda Papadaki ABPI
Nicolas Sireau Findacure
17.00
Final Reflection from Keynote Speakers
Sponsored by
Facilitator
Keynote Speakers
Sir Michael Rawlins MHRA
Sharon Vosmek Astia
17.30
Closing Remarks and Drinks Reception
18.30
Close
Billy Boyle Owlstone Medical
Sam Whitehouse QuantuMDx
Hakan Goker Merck Ventures
Allan Marchington Apposite Capital and Touchstone Innovations
Sara-Jane Dunn Microsoft Research
Peter Jackson The AMR Centre
Lars Gredsted Wellcome Trust
David Pardoe LifeArc
Harriet Fear One Nucleus
floor plan 13
11
10
9
7
8
6
5
2
3
4
1 20
Start-Up Cafe
PA
Ice Cream Van
Entrance to ON Helix
12
14
Lun ch
13 H
15
R
Auditorium
16
Key
19
2
17
Public Engagment Space
PharmaTV
Help Desk
R
Registration Desk
PA
Press Area Tea and Coffee
Partnering
18
H
Toilets UCL Translational Office Workshop
Fire Exits
Lunch
Exhibitors 1 2 3 4 5 6 7 8 9 10 11 12
Astex Pharmaceuticals Findacure LifeArc Agility Health Tech Cambridge Science Centre MedImmune AstraZeneca Propath IT for Starters First Sight Media Potter Clarkson DLRC
13 14 15 16 17 18 19
J A Kemp Chesterford Research Park Babraham Institute Enterprise ChemoMetec Merck United Life Sciences The Milner Therapeutics Institute and Cambridge Academy of Therapeutic Sciences 20 BioData Innovation Centre and Wellcome Genome Campus Conference Centre
The Start-Up CafĂŠ Clustermarket Enplas Innovation Forum The Innovation Practice Press Area Zyme Communications
14
speaker profiles René van der Merwe
Senior Director, Respiratory and Inflammation, MedImmune René is Senior Director, Respiratory and Inflammation, for MedImmune, the global biologics research and development arm of AstraZeneca. Since joining the company in 2009 she has contributed to the discovery and development of a number of candidates in MedImmune’s portfolio. She currently leads the respiratory group within the respiratory, inflammation and autoimmunity (RIA) clinical development team; she led the Tralokinumab clinical team for atopic dermatitis that was recently partnered with LEO, and she currently leads the team for Tezepelumab which is in Phase 2 clinical trials for asthma and atopic dermatitis. Rene is also a member of the leadership team for MedImmune in Cambridge. Prior to joining MedImmune René worked with GlaxoSmithKline, focussing on the RIA, neuroscience and gastrointestinal therapeutic areas, and has also worked with LCG BioScience (a contract research organisation owned by Serono) where she led the medical department. Rene originates from South Africa and gained her medical degree at the University of the Orange Free State in Bloemfontein and her MSc in Clinical Pharmacology at the University of Surrey, and spent the early part of her career working in a number of hospitals in both South Africa and the UK.
Magda Papadaki
Head of Manufacturing Innovation, ABPI Dr Magda Papadaki, is Head of Manufacturing Innovation for ABPI and also shares responsibility for the Medicines Manufacturing Industry Partnership- MMIP. Before joining ABPI, Magda was a Lead Technologist for the Innovate UK Regenerative Medicine programme, looking after the development and commercialisation of new cell and gene therapy products, as well as novel tools and platforms. A stem cell and gene therapy scientist by training, she combines over a decade in research, with regulatory and business experience in the EU and US. Her specialisation includes the development of adaptive pathways and partnerships to reshape the development, manufacturing and adoption of breakthrough treatments and was a member of the global consortium developing the Adaptive Licensing paradigm in MIT, Boston, MA. Magda has worked extensively in the global space of public-private partnerships, including the EU Innovative Medicines Initiative (IMI) and the US/FDA Critical Path initiative. Her industry experience was with Novartis, as DRA and QA/QC Director for Greece and Cyprus. She holds a PhD in Gene Therapy and Stem Cells, an MPhil in Bioscience Enterprise from the University of Cambridge, UK and an MSc in Pharmacology from the University of Oxford, UK.
Nicolas Sireau
Co-Founder and Chairman, Findacure Nick Sireau, PhD, is a Serial Social Entrepreneur with 15+ years experience in medical charities. Most recently, he founded and led a successful consortium developing a treatment for Black Bone Disease, an ultra rare genetic disease affecting his children.
Claire Thompson
Director, Agility Health Tech Claire is a multi-award winning scientist with more than 15 years’ experience in the Pharmaceutical Industry spanning the large multi-nationals GlaxoSmithKline and Pfizer, virtual and Contract Research Organisations. She is the Founder of Agility Health Tech, a consulting and communications firm which works with organisations across the healthcare space to advance their products and raise their profile. Having taken a range of therapeutic products through clinical Phases 1 to 3, she thrives on translating innovative technologies into healthcare products and shaping technical and organisational strategies. She was honoured with the Royal Pharmaceutical Society’s Pharmaceutical Science Award in 2015, and the Academy of Pharmaceutical Sciences’ Medal in 2016. Before founding Agility Health Tech, she was Head of Research and Development with Oxford PharmaScience, an AIM-listed virtual Pharmaceutical company identified as one of the “Top 10 Emerging Technology Companies 2012”. Here she evaluated and identified new technologies for in-licensing, transferring them from universities/companies and directed the scale-up through CROs/CMOs in adherence to EU and FDA cGMP requirements. She also engaged with investors, manufacturing and licensing partners to build capital, product supply and revenue respectively.
Sam Whitehouse COO, QuantuMDx
With 15 years of experience in commercialising scientific research across a range of market areas Sam Whitehouse PhD is QuantuMDx’s Chief Operating Officer. Sam has a wealth of experience in commercial partnering and codevelopment deals, industrial research and managing a large portfolio biotech collaborations. He is COO of British life sciences company QuantuMDx, developers of a portable molecular diagnostic lab to address humanitarian health challenges and detect and track emerging pandemics. Q-POC™ is due for commercialisation in 2018.
workshop 15 Workshop by UCL Translational Research Office Time: 13.00 -13.45 Location: Exhibition Hall, Behind the Partnering Area UCL’s Translational Research Office (TRO) builds on an increasingly vibrant translational culture across the School of Life and Medical Sciences (SLMS) and the wider university community. Through working closely with a broad spectrum of investigators, industry partners and external funding bodies, the TRO facilitates the translation of UCL’s emerging research into therapies, techniques and medical products with therapeutic value. Key activities for the TRO include; strategies for engaging effectively with global and national companies/institutions, responding to corporate and academic needs through networking opportunities, tailored partnerships, projects, and brand-building initiatives.
Jane Kinghorn Director of Translational Research Office
Jane has extensive experience in developing therapies (of differing modalities) to clinical benefit gained over 20 years working in large pharma and academia. Her experience has spanned the drug discovery pathway, leading projects through target validation, lead optimisation, candidate selection through to the clinic and regulatory affairs.
Pamela Tranter Head of Translational Research Group
Pamela joined the UCL Translational Research Office in November 2014. Prior to this Pamela gained extensive experience of drug discovery in the pharmaceutical industry at Novartis/Ciba-Geigy. She has led projects for multiple small molecule and biologics targets for respiratory and thrombosis indications.
Maryam Atakhorrami Head of Business and Innovation Group
Maryam started her career in the medtech industry after joining Philips Corporate Innovation in 2006. She has worked internationally in variety of functions in R&D and strategy, leading a breath of science-based innovation from idea to proof of concept product.
Bringing science to life at Cambridge Science Centre Our independent, educational charity makes science interactive and accessible to all. Inspiring people of all ages through amazing experiences, visitors are encouraged to push, pull and play through highly engaging exhibits, shows and workshops. Each experience sparks and ignites curiosity about science, technology, engineering and maths – known as STEM. Come and see for yourself at ON Helix 2017, and explore our first ever hands-on life science exhibits.
@camsciencecntr
/cambridgesciencecentre
www.cambridgesciencecentre.org
Registered charity No. 1146349
17 July 2018 Cambridge, UK
Translating UK scientific excellence into global therapeutic strategies
onhelix.com #ONHelix18
exhibitor profiles 17
Agility Health Tech. Advancing your products, raising your profile: Consulting and communications for the healthcare and technology sectors. Technology With over 25 years’ experience in the pharmaceutical, materials and nanotechnology sectors, we specialise in getting ideas from concept to market. Strategy We work with our clients to ensure they have the correct vision and strategy in place for their products, company and partnerships. Communications We work with organisations in the healthcare, advanced materials, clean and green tech sectors to raise their profile and ensure the true impact of their science is clearly and impactfully portrayed. www.agilityhealthtech.com Stand 4
Babraham Institute Enterprise is the commercialisation arm of the Babraham Institute. The Institute undertakes innovative life-sciences research to discover the molecular mechanisms that underlie normal cellular processes, with the aim of improving lifelong wellbeing. BIE supports the commercialisation of the Babraham Institute’s science by managing and commercialising the Institute’s IP portfolio. BIE also facilitates collaborations between the Institute and industry, and arranges access to the Institute’s expertise and scientific facilities.
Astex is a leader in innovative drug discovery and development, committed to the fight against cancer and diseases of the central nervous system. Astex is developing a proprietary pipeline of novel therapies and has a number of partnered products being developed under collaborations with leading pharmaceutical companies. Astex is a member of the Otsuka Group, based in Japan. Otsuka Pharmaceutical is a global healthcare company with the corporate philosophy: “Otsuka – people creating new products for better health worldwide.” Otsuka researches, develops, manufactures and markets innovative and original products, with a focus on pharmaceutical products for the treatment of diseases and nutraceutical products for the maintenance of everyday health.
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of Autoimmunity, Neuroscience and Infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca. Stand 7
For more information about Astex Pharmaceuticals, please visit www.astx.com For more information about Otsuka Pharmaceutical, please visit www.otsuka.com/en Stand 1
www.babraham.ac.uk/industry
The Cambridge Academy of Therapeutic Sciences (CATS) is a new initiative based at the University of Cambridge to facilitate the development of new therapeutics and support the education and training of the next generation of world-leading researchers. Working in partnership, we are creating and supporting a vibrant, connected community of scientists working to tackle research and policy challenges. The Academy embraces researchers from across the University of Cambridge, scientists and managers from industry, plus regulatory and policy specialists in the medicines and healthcare sectors.
Stand 15
www.ats.cam.ac.uk Stand 19
Cambridge Science Centre is an independent, educational charity (registered charity no. 1146349) that makes science interactive and accessible to all. Inspiring people of all ages through amazing experiences, visitors are encouraged to push, pull and play through highly engaging exhibits, shows and workshops. Each experience sparks and ignites curiosity about science, technology, engineering and maths – known as STEM. Supported through the Greater Cambridge Greater Peterborough Local Enterprise Partnership (GCGP LEP), Cambridge Science Centre has launched their extended learning programme COSMOS, dedicated to bringing science into communities across East Anglia. Alongside community and school visits, families can access fun activities at home with a free COSMOS online membership. www.cambridgesciencecentre.org Stand 5
18 exhibitor profiles
ChemoMetec develops high quality automated cell counters and advanced image cytometry equipment to help streamline research and production processes for maximum efficiency. Our instruments are deployed in diverse fields from stem cell and cancer biology R&D through to commercial cell therapy production and QC. The products are known for their quality, robustness and high precision plus the easy-to-use yet advanced analysis capabilities – as well as 21-CFR-part-11 capable software. We have a policy of no hidden costs – and that includes no extra service agreement requirements, high levels of support and free software updates. www.chemometec.com Stand 16
DLRC is a leading Regulatory Affairs consultancy that understands the individual needs of clients. Our broad experience supports pharmaceutical and biotechnology companies of all sizes, delivering successful paediatric plans, PRIME and Orphan designations, health authority interactions, IND, CTA and marketing authorisation submission strategies and approvals. During the last year we have received the Queen’s Award for Enterprise in International Trade, won the Hertfordshire Business Awards’ Employer of the Year, and our Founder/Director was presented with the Inspiration award by TOPRA, the regulatory industry professional association. www.dlrc.co.uk Stand 12
Chesterford Research Park is home to leading bioscience innovators including Arecor, Axol Biosciences, Domainex, Isomerase, Oncologica and Oxford Nanopore. Part of the South Cambridge life sciences cluster, Chesterford’s prestigious environment and range of facilities provides flexible and future proofed modern and energy efficient laboratory and office space for both established and early stage biotechnology and pharmaceutical R&D companies. Close to the A11 and M11 this tranquil, low density development is perfectly positioned within 20 minutes of Cambridge. London is reachable in under an hour by train and Stansted airport is just 20 minutes’ drive away.
Clustermarket is an online sharing platform allowing scientists, companies and institutions to share their technology (e.g. lab equipment, service) and infrastructure with their peers. Clustermarket’s goal is to support research by giving all scientists access to existing resources and making it financially sustainable. www.clustermarket.com The Start-Up Café
www.chesterfordresearchpark.com Stand 14
Findacure is a UK charity that is building the rare disease community to drive research and develop treatments. We work to: 1. Empower patient groups to build their patient community, develop as a charity, and drive treatment research and development. We run training workshops and webinars, a peer mentoring programme, and an online resource portal. 2. Promote collaboration between rare disease stakeholders to facilitate treatment development for all. We organising an annual scientific conference and networking events, a student voice essay competition, and we are establishing the first social impact bond for rare disease drug repurposing. www.findacure.org.uk Stand 2
As a video production and streaming specialist, the professional team at First Sight Media have been delivering creative live events, training and promotional videos for over 20 years. Specialising in live and on-demand video streaming, communicating your message through us, over the internet has never been easier. We also offer the ability for you to enhance your conferences and webinars through our bespoke presentation software iPresenter, allowing you to deliver high definition video of your speaker simultaneously with their presentation slides online. Whatever your audience, we can offer a tailored solution to effectively communicate your message through creative multimedia. Visit our website to see examples and get in touch. www.firstsightmedia.co.uk Stand 10
exhibitor profiles 19
The Innovation Forum is a global network of over 10,000 innovative companies, academics, industry professionals, investors and policy makers. Led by our flagship Innovation Forum Leaders Conference now organised for the 3rd time in Cambridge on the 21 and 22 September 2016, we deliver over 40 events annually in 13 global cities on three continents. We also run a global IMAGINE IF! accelerator for early stage pre-seed level healthcare and clean tech ventures. To learn more about our work please visit: www.inno-forum.org Start-Up Café
The Innovation Practice helps companies of all shapes and sizes to untangle business challenges through the delivery of fast paced, interactive workshops. As quoted by Frank Craig, CEO, of Sphere Fluidics on the Babraham Campus: “The Innovation Practice run outstanding workshops on business strategy and performance. These are based on their unique mix of real-world business experience and analytical frameworks. The workshop outputs have significant financial, communication and strategic benefits for any company that the team works with.” Please visit us on our stand at ON Helix.
We offer a tailored suite of services to best meet your requirements. This could range from ad hoc remote support only to on-site support at regular intervals, or a bespoke consultancy agreement to help write the documentation required for your business to gain ISO certification.. www.itforstarters.com Stand 9
www.theinnovationpractice.co.uk Start-Up Café
J A Kemp is one of the largest UK and European patent and trade mark attorney firms, with offices in London, Oxford, Cambridge and Munich. Their attorneys draft, file and prosecute patent and trade mark applications in the UK, Europe and internationally. The firm works for a huge variety of clients, from startups, spinouts and SMEs through to some of the largest corporate clients and most prestigious academic institutions in the world. The majority of the firm’s patent work is in the areas of biotechnology and life sciences, chemistry and pharmaceuticals, and engineering and IT.
LifeArc is the new name for MRC Technology, a medical research charity with a 25 year legacy of helping scientists and organisations turn their research into treatments and diagnostics for patients.
www.jakemp.com
So far, LifeArc’s work has helped to develop four drugs (Keytruda®, Actemra®, Tysabri® and Entyvio®) and a test for antimicrobial resistance.
Stand 13
With nearly 20 years of IT experience, you can be safe in the knowledge that IT for Starters know how to make IT work for you.
The new name reflects the charity’s purpose: to be the arc or bridge between research and improving patients’ lives. LifeArc is pioneering new ways to turn great science into greater patient impact. It brings together a network of partners to tackle specific diseases and directly funds academic and early stage research.
www.lifearc.org Twitter @lifearc1 Stand 3
MedImmune is the global biologics research and development arm of AstraZeneca with candidate biologics and vaccines that currently compromise approximately 50 per cent of AstraZeneca’s overall R&D pipeline. It has one of the most robust and promising pipelines in the biologics industry, with more than 120 biologics in research and development and over 40 projects in clinical stage development. MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic areas, including oncology; respiratory; and cardiovascular and metabolic disease. In addition, the company is opportunistic in infectious disease and vaccines. Approximately 2,200 full-time employees are in the US and UK. MedImmune is headquartered in Gaithersburg, MD – one of AstraZeneca’s three global R&D centres, along with Cambridge, UK and MoIndal, Sweden. www.medimmune.com Stand 6
20 exhibitor profiles
Merck. Our purpose is to solve the toughest problems in life science by collaborating with the global scientific community – and through that, we aim to accelerate access to better health for people everywhere.
www.merck.co.uk
The Milner Therapeutics Institute is a global therapeutic alliance integrated within Cambridge University and dedicated to the conversion of basic science into therapies. The Institute is a collaborative enterprise between Cambridge researchers/clinicians and pharmaceutical/biotech companies and will focus on cancer, neurological disorders and immune-inflammation but any therapeutic area of interest to company partners can be pursued. The research laboratories will open on the Cambridge Biomedical Campus in 2018. The outreach programme of the Institute includes a Consortium of key industry and academic partners which facilitates a number of therapeutic research collaborations and projects and an Affiliate Partnership programme.
Stand 17
www.milner.cam.ac.uk
We provide scientists and engineers with best-in-class lab materials, technologies and services. With the 2015 combination of Merck Millipore and Sigma-Aldrich, we now have a broad portfolio of 300,000 products, an expanded global footprint and an industry-leading eCommerce platform - SigmaAldrich.com. We are dedicated to making research and biotech production simpler, faster and safer.
At Potter Clarkson LLP we recognise the need to understand our clients’ technologies and business objectives in order to devise effective patent strategies. We have a team of over 35 in our biotechnology and chemistry group. Three quarters of the group hold a PhD in a relevant discipline. Many also have research experience in the pharmaceutical industry or academia. We also have patent groups specialising in other technology areas including nanotechnology, computing, electronics, telecommunications, medical engineering, materials science, software, mechanical engineering, textiles, trademarks, etc.” www.potterclarkson.com Stand 11
Stand 19
INNOVATION IN MOLECULAR PATHOLOGY
PROPATH: THE UK’S TRUSTED SPECIALIST IN MOLECULAR PATHOLOGY FOR BIOPHARMACEUTICAL R&D For over three decades, Propath’s GLP and GCP compliant facility has successfully collaborated on studies with biopharmaceutical companies, large and small, across the world. Today we are recognised as a leading specialist in molecular pathology research services, collaborating with clients across the globe to advance their novel immunotherapies. Our teams of scientists and technicians provide expert, regulatory compliant services in immunohistochemistry, biomarker method development, antibody tissue cross reactivity assessment, ISH and FISH, digital pathology image analysis and RNAScope. We also provide an extensive range of services in histopathology, including specialist tissue preparation, routine and special stains and pathology slide evaluation. www.propath.co.uk Stand 8
The Wellcome Trust Sanger Institute is one of the world’s leading genome centres. Through its ability to conduct research at scale, it is able to engage in bold and long-term exploratory projects that are designed to influence and empower medical science globally. The Institute is based at the Wellcome Genome Campus, a world class hub for genomics and bioinformatics. July 2016 saw the opening of its BioData Innovation Centre, enabling a growing number of commercial sector collaborators to join its shared vision of delivering life changing science. The Wellcome Genome Campus Conference Centre boasts world-class event and meeting spaces designed for knowledge sharing in the scientific research community. New for 2017 is a service providing administrative and logistical support for those running their events here. www.wellcomegenomecampus.org Stand 20
exhibitor profiles 21
United Life Sciences is a strategic partnership representing over 1,200 life science and healthcare organisations across the UK and internationally. The ULS collaboration has member and the wider UK life science sector benefit at the heart of its purpose and is the basis for all joint activities. It strives to avoid duplication of effort and coordinates the five organisations’ activities whilst recognising each other’s areas of strength so that member companies can benefit from more effective and coherent sector support.
Zyme Communications provides strategic and specialist communications services for the life science sector. Based in Cambridge and Manchester in the UK, and with clients across Europe and the USA, Zyme is focused on supporting companies to raise their profile and generate interest from commercial leads, investors and partners. With an international network of life science trade media contacts and a strong technical understanding, Zyme is committed to delivering value and results from objective-lead communications. www.zymecommunications.com
www.unitedlifesciences.org
Press Area Stand 18
Babraham-Advert-230617-NA.pdf
1
23/06/2017
14:22
THE CAMBRIDGE BUILDING Premium conference and meeting room spaces at the Babraham Research Campus. > 200 capacity tiered lecture theatre. > Flexible spaces for meetings and seminars. > State of the art audio-visual. > Full catering and hospitality services available. > Easily accessible for A11, M11 and central Cambridge. > Free car parking. > Peaceful surroundings.
To book call 01223 496 215 or email info@babraham.co.uk W W W. B A B R A H A M . C O M
22 dates for your diary 2017 SEP 06
BioWednesday Gowling WLG, London
NOV 01
BioWednesday Bristows LLP, London
SEP 20
Network Meeting Deloitte, Cambridge
NOV 15
Leadership Seminar Cambridge
OCT 04
BioWednesday Queen Mary BioEnterprises, London
NOV 22
Network Meeting Stevenage Bioscience Catalyst, Stevenage
OCT 10
Leadership Seminar Babraham Research Campus, Cambridge
DEC 13
Genesis Welcome Reception London
OCT 11
M11 Health Enterprise Forum Harlow
DEC 14
Genesis QEII Centre, London
OCT 18
Network Meeting Mills & Reeve, Cambridge
Facilities Management One Nucleus provides project management for all your laboratory fit-outs. • • • •
Setting up of laboratory equipment service contracts Building maintenance contracts Insurance Purchasing
Contact: richard@onenucleus.com Tel: 01223 896453
• Cleaning contracts • Utilities • Budgeting
London’s premier Life Science & Healthcare networking conference
genesis 2017 14 December 2017 QE II Centre Westminster, London, UK
#ongc17 genesisconference.com
We are pioneers. We find new ways to turn great science into greater patient impact. lifearc.org info@lifearc.org +44 (0) 20 7391 2700